Colorectal Cancer

Interim data from the phase 2 AZUR-1 trial showed sustained clinical complete responses with dostarlimab monotherapy in dMMR/MSI-H locally advanced rectal cancer.

Catch up on key data in colorectal, pancreatic, and hepatocellular cancers presented at the ESMO Gastrointestinal Cancers Congress 2026.

A molecular residual disease test identified which patients with resected colorectal liver metastases gained a survival benefit from adjuvant chemotherapy.

Preliminary data from the phase 1/2 TARGET-D 101 trial showed a manageable safety profile for VS-7375 across KRAS G12D–mutated solid tumors.

Retrospective data showed that GLP-1 receptor agonist use was associated with a 51% reduction in colorectal cancer odds among patients with inflammatory bowel disease.

Zanzalintinib plus atezolizumab did not elicit a statistically significant overall survival advantage over regorafenib in patients with non–MSI-H mCRC without active liver metastases.

The European Commission has approved encorafenib plus cetuximab and FOLFOX as the first BRAF-targeted regimen authorized in the EU for first-line BRAF V600E–mutant metastatic colorectal cancer.

A nurse-integrated mobile exercise app showed high usability, 80% exercise adherence, and significant fatigue improvements in a pilot study of adolescents with cancer.

Cost-utility analysis of the CHALLENGE trial showed structured exercise following adjuvant chemotherapy for colon cancer is cost-saving and improves QALYs.

FOLFIRI is viable as a chemotherapy backbone with the BREAKWATER regimen as a treatment for patients with frontline BRAF V600E-mutant metastatic colorectal cancer.

Data from the phase 3 CIRCULATE trial may justify ctDNA-guided treatment escalation strategies in pMMR stage II colon cancer.

A remote mobile health intervention tripled the odds of CRC screening completion in at-risk childhood cancer survivors in the randomized ASPIRES trial.

Adjuvant aspirin did not improve disease-free survival vs placebo in patients with stage III colorectal cancer who received standard adjuvant chemotherapy.

Serial ctDNA assessment after 3 months of adjuvant chemotherapy stratified recurrence risk and identified which patients with resected CRC benefit from extended treatment.

The European Medicine Agency’s CHMP has adopted a positive opinion for encorafenib plus cetuximab and mFOLFOX6 in this treatment-naïve mCRC population.

Updated interim data from a phase 1/2 study of the DR5 agonist ozekibart plus FOLFIRI demonstrated a 20% ORR and 87% DCR in late-line colorectal cancer.

The incidence rates of breast cancer and colorectal cancer have been on the rise in patients under 50 years for the past several years.

Marc Lehrer Greenwald, MD, spoke with CancerNetwork® about how North Shore University Hospital treats young patients with colorectal cancer.

Marwan G. Fakih, MD, discussed many of the factors he considers when deciding on a treatment for a patient with metastatic colorectal cancer.

Development of the oral DHX9 inhibitor, ATX-559, has been halted following adverse events in a phase 1/2 trial of patients with metastatic solid tumors.

Results from the BREAKWATER trial led to the traditional approval of encorafenib plus cetuximab and fluorouracil-based chemotherapy in BRAF-mutated CRC.

Phase 2 CRDF-004 findings show that adding onvansertib to FOLFIRI and bevacizumab improves PFS in first-line RAS-mutated metastatic colorectal cancer.

Encorafenib, cetuximab, and FOLFIRI improved PFS vs in treatment-naive BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER trial.

Prior phase 1 data support the fast track designation for pelareorep as a treatment for those with KRAS-mutated microsatellite stable colorectal cancer.

Treatment with zanzalintinib plus atezolizumab led to improvements in OS and PFS vs regorafenib alone in patients with metastatic colorectal cancer.